Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain

References

• CleelandCSGoninRHatfieldAKPain and its treatment in outpatients with metastatic cancerN Engl J Med199433095925967508092
   PubMed Web of Science ®Google Scholar
• Van den Beuken-van EverdingenMHde RijkeJMKesselsAGSchoutenHCvan KleefMPatijnJPrevalence of pain in patients with cancer: a systematic review of the past 40 yearsAnn Oncol20071891437144917355955
   PubMed Web of Science ®Google Scholar
• MercadanteSFultaroFWorld Health Organization guideline: a reappraisalAnn Oncol200516Suppl 4iv132iv13515923413
   PubMed Web of Science ®Google Scholar
• CaraceniAHanksGKaasaSUse of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCLancet Oncol2012132e58e6822300860
   PubMed Web of Science ®Google Scholar
• QuigleyCThe role of opioids in cancer painBMJ2005331752082582916210282
   PubMed Web of Science ®Google Scholar
• HuiDBrueraETransdermal fentanyl: not ready for front lineJ Palliat Care200925430020131589
   PubMed Web of Science ®Google Scholar
• TassinariDDrudiFRosatiMMaltoniMTransdermal opioids as front line treatment of moderate to severe cancer pain: a systemic reviewPalliat Med201125547848721708854
   PubMed Web of Science ®Google Scholar
• WiffenPJMcQuayHJOral morphine for cancer painCochrane Database Syst Rev20074CD00386817943804
   PubMed Web of Science ®Google Scholar
• JadadARBrowmanGPThe WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluationJAMA199527423187018737500538
   PubMed Web of Science ®Google Scholar
• CachiaEAhmedzaiSHTransdermal opioids for cancer painCurr Opin Support Palliat Care201151151921325999
   PubMedGoogle Scholar
• TassinariDSartoriSTamburiniEAdverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literatureJ Palliat Med200811349250118363493
   PubMed Web of Science ®Google Scholar
• TassinariDSartoriSTamburiniETransdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trialsJ Pallliat Care2009253172180
   PubMed Web of Science ®Google Scholar
• MercadanteSBrueraEOpioid switching: a systematic and critical reviewCancer Treat Rev200632430431516624490
   PubMed Web of Science ®Google Scholar
• DaleOMoksnesKKaasaSEuropean Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side-effects. A systematic reviewPalliat Med201125549450321708856
   PubMed Web of Science ®Google Scholar
• de StoutzNBrueraESuarez-AlmazorMOpioid rotation for toxicity reduction in terminal cancer patientsJ Pain Symptom Manage19951053783847673770
   PubMed Web of Science ®Google Scholar
• BrueraEPereiraJWatanabeSBelzileMOpioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphineCancer19967848528578756381
   PubMed Web of Science ®Google Scholar
• MercadanteSOpioid rotation in cancer pain: rationale and clinical aspectsCancer19998691856186610547561
   PubMed Web of Science ®Google Scholar
• MercadenteSPorzioGFerreraPSustained release oral morphine versus transdermal fentanyl and oral methadone in cancer pain managementEur J Pain20081281040104618353696
   PubMed Web of Science ®Google Scholar
• WolffRFAuneDTruyersCSystematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe painCurr Med Res Opin201228583384522443154
   PubMed Web of Science ®Google Scholar
• KoyyalaguntaDBrueraESolankiDRA systematic review of randomized trials on the effectiveness of opioids in cancer painPain Physician201215Suppl 3ES39ES5822786461
   PubMed Web of Science ®Google Scholar
• SlatkinNEOpioid switching and rotation in primary care: implementation and clinical utilityCurr Med Res Opin20092592133215019601703
   PubMed Web of Science ®Google Scholar
• SkaerTLTransdermal opioids for cancer painHealth Qual Life Outcomes200642416573839
   PubMed Web of Science ®Google Scholar
• MercadanteSCaraceniAConversion ratios for opioid switching in the treatment of cancer pain: a systematic reviewPalliat Med201125550451521708857
   PubMed Web of Science ®Google Scholar
• BradleyAMValgusJMBernardSConverting transdermal fentanyl: avoidance of underdosingJ Palliat Med201316440941123477303
   PubMed Web of Science ®Google Scholar
• AshburnMLipmanAManagement of pain in the cancer patientAnesth Analg19937624024168424523
   PubMed Web of Science ®Google Scholar
• FinePGPortenoyRKAd Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing best practices for opioid rotation: conclusions of an expert panelJ Pain Symptom Manage200938341842519735902
   PubMed Web of Science ®Google Scholar
• KnotkovaHFinePFPortenoyRKOpioid rotation: the science and the limitations of the equianalgesic dose tableJ Pain Symptom Manage200938342643919735903
   PubMed Web of Science ®Google Scholar
• HanksGWFallonMTTransdermal fentanyl in cancer pain. Conversion from oral morphineJ Pain Symptom Manage1995102877537319
   PubMed Web of Science ®Google Scholar
• WebsterLRFinePGOverdose deaths demand a new paradigm for opioid rotationPain Med201213457157422458858
   PubMed Web of Science ®Google Scholar
• GrondSRadbruchLLehmannKAClinical pharmacokinetics of transdermal opioids: focus on transdermal fentanylClin Pharmacokinet2000381598910668859
   PubMed Web of Science ®Google Scholar
• DonnerBZenzMTrybaMStrumpfMDirect conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer painPain19966435275348783318
   PubMed Web of Science ®Google Scholar
• RadbruchLElsnerFClinical experience with transdermal fentanyl for the treatment of cancer pain in GermanyKeio J Med2004531232915096725
   PubMedGoogle Scholar
• MystakidouKParpaETsilikaEPain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, and III transfersJ Pain20045211913215042520
   PubMed Web of Science ®Google Scholar
• MercadanteSCasuccioATirelliWGiarrantanoAEquipotent doses to switch from high doses of opioids to transdermal buprenorphineSupport Care Cancer200917671571819104845
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGFulfanoFSwitching from transdermal drugs: an observational ‘N of 1’ study of fentanyl and buprenorphineJ Pain Symptom Manage200734553253817629666
   PubMed Web of Science ®Google Scholar
• AurilioCPaceMCPotaVOpioids switching with transdermal systems in chronic cancer painJ Ex Clini Cancer Res20092861
   PubMed Web of Science ®Google Scholar
• SittiRLikarRNautrupBPEquipotent dose of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort studyClin Ther200527222523715811486
   PubMed Web of Science ®Google Scholar
• FreyeEAnderson-HillemacherARitzdorfILevyJVOpioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patientsPain Pract20077212312917559481
   PubMedGoogle Scholar
• LikarRKrainerBSittiRChallenging the equipotency calculation for transdermal buprenorphine: four case studiesInt J Clin Pract200862115215618173815
   PubMed Web of Science ®Google Scholar
• DaviesANDickmanAReidCThe management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and IrelandEur J Pain200913433133818707904
   PubMed Web of Science ®Google Scholar
• HaugenDFHjermstadMJHagenNAssessment and classification of cancer breakthrough pain: a systematic literature reviewPain2010149347648220236762
   PubMed Web of Science ®Google Scholar
• KornickCASantiago-PalmaJMorylNet al. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic painDrug Saf2003261395197314583070
   PubMed Web of Science ®Google Scholar
• BreitbartWChandlerSEagelBAn alternative algorithm for dosing of transdermal fentanyl for cancer-related painOncology (Williston Park)200014569570510853461
   PubMed Web of Science ®Google Scholar
• PayneRChandlerSEinhausMGuidelines for the clinical use of transdermal fentanylAnticancer Drugs19956350537606038
   PubMed Web of Science ®Google Scholar
• WenWLynchSYMuneraCApplication site adverse events associated with the buprenorphine transdermal system: a pooled analysisExpert Opin Drug Saf201312330931923506252
   PubMed Web of Science ®Google Scholar
• DurandCAlhanmmadAWillettKPractical considerations for optimal transdermal drug deliveryAm J Health Syst Pharm201269211612422215357
   PubMed Web of Science ®Google Scholar
• FDA [homepage on the Internet]Public Health Advisory: risk of burns during MRI scans from Transdermal drug patches with metallic backings Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm111313.htmAccessed May 19, 2014
   Google Scholar
• HongIGabayMLadolceASafety concerns involving transdermal patches and magnetic resonance imaging (MRI)Hospital Pharmacy20104510771778
   Google Scholar
• SouthamMATransdermal fentanyl therapy: System design, pharmacokinetics and efficacyAnticancer Drugs19956Suppl 329347606033
   PubMed Web of Science ®Google Scholar
• PortenoyRKSouthamMGuptaSKTransdermal fentanyl for cancer pain. Repeated dose pharmacokinetics and efficacyAnesthesiology199378136438424569
   PubMed Web of Science ®Google Scholar
• DahanAYassenARombergRBuprenorphine induces ceiling in respiratory depression but not in analgesiaBr J Anaesth200696562763216547090
   PubMed Web of Science ®Google Scholar
• DahanAOpioid-induced respiratory effects: new data on buprenorphinePalliat Med200620Suppl 1S3S816764215
   PubMed Web of Science ®Google Scholar
• OverholserBRFosterDROpioid pharmacokinetic drug-drug interactionsAm J Manage Care201117Suppl 11S276S287
   PubMedGoogle Scholar
• McCance-KatzEFSullivanLNallaniSDrug interaction of clinical importance among the opioids, methadone, and buprenorphine, and other frequently prescribed medications: a reviewAm J Addict201019141620132117
   PubMed Web of Science ®Google Scholar
• JumbelicMIDeaths with transdermal fentanyl patchesAm J Forensic Med Pathol2010311182119918162
   PubMed Web of Science ®Google Scholar
• FDA [homepage on the Internet]Safety warnings regarding use of fentanyl transdermal (skin) patches Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051739.htmAccessed May 19, 2014
   Google Scholar
• FDA [homepage on the Internet]FDA issues second safety warning on fentanyl skin patch: deaths and serious injuries from improper use Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109046.htmAccessed May 19, 2014
   Google Scholar
• FDA [homepage on the Internet]FDA reminds the public about the potential for life-threatening harm from accidental exposure to fentanyl transdermal systems (patches) Available from: http://www.fda.gov/drugs/drugsafety/ucm300747.htmAccessed May 19, 2014
   Google Scholar
• FDA [homepage on the Internet]FDA Drug Safety Communication: FDA requiring color changes to Duragesic (fentanyl) pain patches to aid safety-emphasizing that accidental exposure to used patches can cause death Available from: http://www.fda.gov/drugs/drugsafety/ucm368902.htmAccessed May 19, 2014
   Google Scholar
• HeiskanenTMatzkeSHaakanaSTransdermal fentanyl in cachectic cancer patientsPain20091441–221822219442446
   PubMed Web of Science ®Google Scholar
• van OjikALJansenPAFBruwersJRvan RoonENTreatment of chronic pain in older people evidence-based choice of strong-acting opioidsDrugs Aging201229861562522765848
   PubMed Web of Science ®Google Scholar
• PloskerGlBuprenorphine 5, 10, and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant painDrugs201171182491250922141389
   PubMed Web of Science ®Google Scholar
• MichelEAndersonBZernikowBBuprenorphine TTS for children – a review of the drug’s clinical pharmacologyPaediatr Anaesth201121328029021091589
   PubMed Web of Science ®Google Scholar
• ZernikowBMichelECraigFAndersonBJPediatric palliative care: use of opioids for the management of painPaediatr Drugs200911212915119301934
   PubMedGoogle Scholar